RVNC Revance Therapeutics, Inc.

20.75
+0  (2%)
Previous Close 20.35
Open 20.55
Price To book 3.29
Market Cap 608.37M
Shares 29,319,000
Volume 82,985
Short Ratio 19.71
Av. Daily Volume 172,002

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2H 2017.
RT002
Plantar fasciitis
Phase 3 endpoints not met June 2016
RT001 - REALISE 1
Lateral Canthal (Crow’s Feet) Lines
Phase 2 full data due 2Q 2017.
RT002
Cervical dystonia
Phase 3 completion of enrollment announced March 8, 2017. Data due 4Q 2017.
RT002 - SAKURA
Moderate to severe glabellar (frown) lines

Latest News

  1. Revance Therapeutics, Inc. – Value Analysis (NASDAQ:RVNC) : April 20, 2017
  2. Revance Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : RVNC-US : April 19, 2017
  3. Revance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : March 21, 2017
  4. Revance Therapeutics, Inc. :RVNC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017
  5. Revance Completes Enrollment in Phase 3 Pivotal Trials of RT002 Injectable for the Treatment of Glabellar (Frown) Lines
  6. Revance Announces BELMONT Phase 2 Clinical Data to Be Presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting
  7. Edited Transcript of RVNC earnings conference call or presentation 27-Feb-17 9:30pm GMT
  8. Revance reports 4Q loss
  9. Revance Releases Fourth Quarter and Full Year 2016 Results
  10. Revance to Participate in Upcoming Investor Conferences
  11. Revance Therapeutics to Release Fourth Quarter 2016 Financial Results Monday, February 27, 2017
  12. Revance Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : RVNC-US : January 31, 2017
  13. BELMONT Phase 2 Clinical Data to be Presented at IMCAS World Congress 2017
  14. Revance Presents Clinical Data for RT002 Injectable at TOXINS 2017
  15. Revance Provides Clinical Milestones and Financial Outlook for 2017
  16. Revance Therapeutics, Inc. – Value Analysis (NASDAQ:RVNC) : December 15, 2016
  17. Revance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : December 14, 2016
  18. Revance Announces Positive 24-Week Duration of Effect in Interim Results from Phase 2 Cervical Dystonia Trial
  19. Revance Announces Initiation of Subject Dosing in the SAKURA Phase 3 Clinical Program of RT002 Injectable for the Treatment of Glabellar (Frown) Lines
  20. Revance to Participate in the 28th Annual Piper Jaffray Healthcare Conference